Article

Human Papillomavirus Vaccines Six Years After Approval.

Vedantra Pharmaceuticals, Cambridge, MA 02139
Annual review of medicine (Impact Factor: 9.94). 11/2012; DOI: 10.1146/annurev-med-061511-125226
Source: PubMed

ABSTRACT Human papillomavirus vaccines were developed beginning in the early 1990s. Two similar vaccines were approved in 2006 and 2009 following extensive clinical testing. Both vaccines prevent HPV infection. Implementation of these vaccines is the next challenge. Expected final online publication date for the Annual Review of Medicine Volume 64 is January 07, 2013. Please see http://www.annualreviews.org/catalog/pubdates.aspx for revised estimates.

0 Bookmarks
 · 
96 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human papillomavirus (HPV) infection is associated with cervical cancer, but whether it is involved in colorectal carcinogenesis is controversial. We conducted a meta-analysis to evaluate the association between HPV and colorectal adenocarcinoma. A search of the MEDLINE database was performed using the MESH terms "HPV", "human papillomavirus", and "colon cancer", "rectal cancer", "colorectal cancer". The prevalence of HPV infection in colorectal cancer was estimated by pooling data from 16 studies (involving 1436 patients) published up to July 2012, taking into consideration methodological heterogeneity between studies. The association of HPV and colorectal cancer risk was estimated from case-control studies. HPV prevalence was 31.9% (95% CI:19.3% to 47.9%). It was lowest in Europe (14.1%, 95% CI: 4.9%-34.1%) and highest in South America (60.8%, 95% CI = 42.7%-76.4%). Eight studies presented results of HPV typing in 302 HPV-positive colorectal carcinomas. HPV18 was the virus more frequently found in Asia 73.34% (95% CI 44.9 -90.7%) and Europe, (47.3% [95% CI 34.5 - 60.4]) of colorectal cancer cases. In contrast, HPV16 was the virus more prevalent in tumours from South America (58.3% [95%CI 45.5 -69.9%]). The analysis of five case-control studies showed AN increase in colorectal carcinoma risk with HPV positivity (OR 10.04 [95% CI 3.7 - 27.5]). The results provide quantitative evidence for an association between HPV infection and colorectal cancer risk. This article is protected by copyright. All rights reserved.
    Colorectal Disease 04/2013; 15(8). DOI:10.1111/codi.12257 · 2.02 Impact Factor